Free Trial

HilleVax Q3 2023 Earnings Report

HilleVax logo
$1.92 +0.03 (+1.32%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HilleVax EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q3 2023
Time
N/A

HilleVax Earnings Headlines

Kamala’s final humiliation
Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behind closed doors with some of America’s savviest investors. The obscure, little-known companies we believe could 5x, even 10x, under Trump’s second term…
HilleVax Reports Q3 Financial Results Amid Strategic Planning
AVXL Aug 2024 12.500 put (AVXL240823P00012500)
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat